Predictors of left ventricular dysfunction following mitral valve repair for mitral regurgitation: Reply  by Matsumura, Takayoshi et al.
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Sredictors of Left Ventricular
ysfunction Following Mitral
alve Repair for Mitral Regurgitation
e read the study by Matsumura et al. (1) and the accompanying
ditorial by Wisenbaugh (2) with great interest. Unfortunately, in
eveloping countries, rheumatic heart disease remains the major
ause for severe mitral regurgitation. Furthermore, many patients
re seen for the first time when adverse echocardiographic char-
cteristics such as an ejection fraction 60% or an end-systolic
iameter 45 mm are already present. The results of mitral valve
eplacement under these circumstances have been clearly docu-
ented to be poor (3), and an often-asked question is whether
itral valve repair—although more difficult with rheumatic disease
ompared to degenerative disease—would not be preferable in
hese patients.
Although not stated clearly in the report or editorial, it would
ppear that the echocardiographic predictors of a poor outcome
ollowing mitral valve repair are numerically similar if not identical
o those previously defined for mitral valve replacement. This is
isappointing because given the well-known benefits of valve
epair in terms of preservation of chordal-ventricular continuity,
ne would have anticipated that postoperative left ventricular (LV)
unction could be guaranteed at lower preoperative ejection frac-
ions or higher end-systolic diameters.
Also of great interest, but not commented upon, is the fact that
n a significant number of patients, postoperative ejection fraction
as higher compared to the preoperative value (Fig. 1 in Mat-
umura et al. [1]). Although preservation of ejection-phase indices
f LV function have been well documented with mitral valve
epair, the apparent increase in ejection fraction noted by Mat-
umura et al. (1) is a less known phenomenon, especially as the
reatest impact of any mitral valve surgery is an immediate and
ignificant decline in the preload. A postoperative reduction in
fterload has been documented in some studies of mitral valve
epair (4,5) and is supported in the current study by a reduction in
he end-systolic diameter. However, postoperative reduction in
fterload in the studies by Lessana et al. (4) and Bonchek et al. (5)
id not result in an increase in ejection fraction but was sufficient
nly to prevent a significant decline in the ejection fraction. A
epressed preoperative contractile state, which may have improved
ith removal of chronic volume overload, is also unlikely as the
ajority of patients with improvement in ejection fraction had
ormal ejection fractions to begin with (6).
Finally, it would be of interest to know what proportion of
atients had moderate mitral regurgitation, as most guidelines
equire that mitral regurgitation be considered significant before
ontemplating operative intervention.
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EPLY
e appreciate the comments by Dr. Essop regarding our recent
eport on left ventricular (LV) dysfunction after mitral valve repair
1).
First, as Essop points out, echocardiographic predictors of a
oor outcome in our study might be similar to those previously
eported for mitral valve replacement. However, to compare mitral
alve repair with mitral valve replacement, we must interpret our
ndings carefully because our study was not designed so. Some
revious data suggest that LV function is preserved better after
itral valve repair than after mitral valve replacement (2,3).
urther studies are needed to compare their echocardiographic
redictors of a poor outcome. And even if echocardiographic
redictors are similar, we believe that mitral valve repair is the
rocedure of choice that brings the better quality of life whenever
complete repair is expected.
Second, we must admit that only two factors, the preoperative
jection fraction and the LV end-systolic diameter, cannot fully
xplain which patients will have the better postoperative ejection
raction and which patients will not. Our results showed that the
V ejection fraction decreased significantly after mitral valve repair
s a whole, but that in some patients the postoperative ejection
raction can be higher than the preoperative one. In the study by
essana et al. (4) that Essop refers to, 26 patients underwent
atheterization 2 to 60 months after mitral valvuloplasty (average
4 months). Mean ejection fraction decreased from 0.58  0.11 to
.52  0.11. Ejection fraction in individual patients rose in 8 and
ell in 18. In the other study by Bonchek et al. (5), 10 patients were
tudied with catheterization one week postoperatively. Mean
jection fraction was unchanged (0.66  0.1 vs. 0.62  0.1).
jection fraction in individual patients rose in three, was un-
hanged in one, and fell in six. Although their shorter follow-up
eriods and our use of recently developed surgical techniques may
reclude simple comparison between their results and ours, our
esults are at least not inconsistent with their results (5).
The improved ejection fraction in some patients can be consid-
red to reflect the increased LV contractility as stated in our report.
tarling et al. (6) showed that contractile function is impaired in
ome patients with long-term mitral regurgitation and a normal
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May 19, 2004:1925–7jection function, and that impaired contractile function may not
e irreversible in all these patients. As Essop mentions, Wisen-
augh (7) reported that, among patients with mitral regurgitation,
0 of 14 with ejection fraction 0.60 and 4 of 13 with ejection
raction 0.60 had muscular dysfunction and that others did not.
is results and ours clearly show that LV dysfunction cannot be
redicted with ejection fraction alone. It may be important to us to
cknowledge that ejection fraction decreases after surgery in
eneral, but that in some patients it can increase owing to
mproved contractility.
Finally, among 171 patients in our analysis of LV dysfunction,
5 patients had moderate mitral regurgitation, and 106 patients
ad severe mitral regurgitation.
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77:515–25. composite Confusion
n their retrospective post hoc analysis of the CADILLAC study,
r. Cox et al. (1) state that the one-year composite adverse event
ate (death, reinfarction, disabling stroke, or target vessel revascu-
arization [TVR]) was greater after optimal percutaneous translu-
inal coronary angioplasty (PTCA) than routine stenting (21.9%
s. 13.8%, p  0.001) and that this was driven largely by increased
ates of ischemic TVR (19.1% vs. 9.1%, p  0.001). As a result,
hey conclude that early and late outcomes can be further improved
ith routine stent implantation.
The conclusion seems excessive given results glossed over as
imply nonsignificant. Perhaps what the investigators might have
tated was that the difference in the composite outcome was driven
ntirely by the least clinically relevant and softest outcome event,
amely TVR. Indeed, as shown in Table 3 of their study, the risks
f death, recurrent myocardial infarction (MI), and disabling
troke were all higher (but not statistically significantly so) with
tenting at 30 days. Moreover, at one year the relative increase in
he risk of death with stenting was 31.3% and the absolute increase
as 1.0%; this is about the same as the benefit of tissue plasmin-
gen activator over streptokinase and far larger than any putative
enefit of glycoprotein IIb/IIIa inhibitors in acute coronary syn-
romes. I cannot help but believe that had the estimates for the
ndividual outcome events been reversed (that is, favoring stenting)
eaders would have seen phrases such as “strong trends” or “lack of
tatistical power” as an explanation. This worrisome increase in
linically important outcome events, also seen in other studies of
tents in MI, should not be dismissed as just play of chance or as
ot significant. I would have thought it might merit a line or two
n the discussion.
Could the investigators please provide readers with the differ-
nces between stent and optimal PTCA groups for: 1) death and
isabling stroke, and 2) death, disabling stroke, and recurrent MI
t 30 days and at 1 year?
Finally, should we not discard this silly notion of composite end
oints that equate a death and a disabling stroke as equivalent to
recurrent revascularization procedure? Is that how our patients
iew these events? Interpretive difficulties are sure to arise in
roblematic reports, such as the study by Cox et al. (1), where
lements of the composite go in opposite directions (the treatment
educes TVR, but death, disabling stroke, and recurrent MI may
e increased) (2). Careful wordsmithing often gives the illusion
hat all elements of the composite end point are favorably affected
3).
In the absence of a consensus-weighting scheme for elements of
composite, perhaps we need a hierarchical nomenclature for
omposites that make the results more transparent, particularly in
he published abstract. For example, one could state that the
omposite was significantly lower among patients randomized to
tenting (21.9% vs. 13.8%, p  0.001, death [inc-ns], disabling
troke [inc-ns], re-MI [nd-ns], TVR [dec-sig]). All elements of
he composite are reported, and they are ranked starting with death
nd followed by those of lesser clinical importance. Those elements
eemed to be hard and objective are capitalized, whereas those that
re more subjective or clinician-driven are given in lowercase. It is
pecified whether the point estimate is in keeping with an increase
inc), decrease (dec), or no difference (nd); and whether there is
onventional statistical significance (sig) or not (ns).
